代谢模型的预测使得通过精确的益生菌能够对微生物进行有针对性的微生物组操纵
Georgios Marinos1, Inga K Hamerich2, Reena Debray3
1Research Group Medical Systems Biology, University Hospital Schleswig-Holstein Campus Kiel, Kiel University, Kiel, Schleswig-Holstein, Germany.
Microbiology spectrum
|January 17, 2024
概括
研究人员确定了精确的益生菌,以选择性地增加有益的肠道细菌. 代谢建模预测了像L-氨酸这样的化合物,这些化合物在实验中得到验证,可以在体外和体内增加向微生物的丰度.
科学领域:
- 微生物组研究的研究.
- 代谢工程是代谢工程.
- 主体-微生物相互作用
背景情况:
- 主体-微生物相互作用对健康至关重要,但有针对性的调制仍然具有挑战性.
- 现有的方法缺乏操纵微生物组合的特异性.
研究的目的:
- 确定精确的益生菌,可以选择性地增加特定有益微生物群物种的丰富性.
- 开发一种代谢建模方法,用于设计精密的益生菌.
主要方法:
- 利用基于约束的代谢建模来预测精确的益生菌.
- 设计了使用两个成员的Caenorhabditis elegans微生物群体的实验.
- 验证的预测精度益生菌在体外和体内.
主要成果:
- 代谢建模确定了潜在的精确益生菌.
- 四种化合物 (L-氨酸,L-氨酸,D-曼尼托尔,γ-氨基黄油酸) 选择性地增加了目标物种的丰度.
- 在体内,L-氨酸显示出有效性,增加了宿主中的向微生物水平.
结论:
- 代谢建模是设计精确益生菌的有效工具.
- 精密的益生菌可以选择性地调节微生物组合.
- 这种方法是开发基于微生物组的向治疗方法的基石.
相关概念视频
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Probiotics
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Introduction to the Human Microbiota
Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity, and disease...
Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...


